BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22137341)

  • 21. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
    Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
    Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of phthalates on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 activities in human and rat testes.
    Yuan K; Zhao B; Li XW; Hu GX; Su Y; Chu Y; Akingbemi BT; Lian QQ; Ge RS
    Chem Biol Interact; 2012 Feb; 195(3):180-8. PubMed ID: 22214983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
    Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
    Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
    Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
    J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
    Poirier D
    Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinnamates and cinnamamides inhibit fungal 17beta-hydroxysteroid dehydrogenase.
    Kristan K; Starcević S; Brunskole M; Rizner TL; Gobec S
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):239-41. PubMed ID: 16337334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
    Cortés-Benítez F; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
    Wood J; Bagi CM; Akuche C; Bacchiocchi A; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook JH; Conrad P; Dixon BR; Ehrlich PP; Gane T; Gunn D; Joe T; Johnson JS; Jordan J; Kramss R; Liu P; Levy J; Lowe DB; McAlexander I; Natero R; Redman AM; Scott WJ; Town C; Wang M; Wang Y; Zhang Z
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4965-8. PubMed ID: 16806919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents.
    Clark RF; Zhang T; Wang X; Wang R; Zhang X; Camp HS; Beutel BA; Sham HL; Gu YG
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1961-5. PubMed ID: 17267221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3.
    Vicker N; Bailey HV; Day JM; Mahon MF; Smith A; Tutill HJ; Purohit A; Potter BVL
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.